The groundbreaking success of Sildenafil undeniably revolutionized the medication landscape, but placing funds in companies primarily reliant on unbranded versions presents a uncertain picture. Although early earnings were substantial, the end of patents and the rise of less expensive alternatives have weakened the customer base. Consequently, a th